尤瑞克林联合依达拉奉治疗中重度急性脑梗死的随机临床研究  

Randomized clinical study of urinary kallidinogenase combined with edaravone treating moderate and severe acute cerebral infarction

作　　者：王展航[1] 

机构地区：[1]广州中医药大学祈福医院神经内科,广东省广州,511495

出　　处：《中国基层医药》2012年第5期680-682,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的观察尤瑞克林联合依达拉奉治疗中重度急性脑梗死的有效性和安全性。方法对84例急性脑梗死患者随机分为两组：对照组给予依达拉奉治疗，治疗组在对照组基础上再加尤瑞克林，其它内科常规治疗相同。结果比较两组治疗14d前后美国国立卫生院神经功能缺损评分（NIHSS）和日常生活能力（ADL）的变化。治疗后治疗组和对照组NIHSS评分均有改善（P〈0．01），但治疗组改善更明显（P〈0．01）；两组ADL水平均较治疗前上升（P〈0．01），但治疗组上升更明显（P〈0．01）。结论尤瑞克林可选择性扩张缺血区血管，开放侧枝循环，促进新生血管形成，联合依达拉奉治疗中重度急性脑梗死，可明显改善神经功能缺损，降低致残率，安全性高。Objective To explore the effect and safety of urinary kallidinogenase combined with edaravone in treating moderate and severe acute cerebral infarction. Methods 84 patients who had acute cerebral infarction were randomly divided into 2 groups, control group was given edaravone, treatment group was added urinary kallidinogenasc based on control group, other conventional medical treatments were same. Results After 14 days treatment, the change of National Institute of Health stroke scale（NIHSS） and Activities of Daily Living（ADL） before and after the 14 days were compared. After the treatment, NIHSS of urinary kallidinogenase group and control group both improved （P 〈 0.01 ） ,urinary kallidinogenase group improved more significantly, and had significant difference compared with control group（P 〈0.01 ）. ADL level of the two groups both went up（P 〈0.01 ） ,urinary kallidinogenase group went up more significantly, and had the significant difference compared with controlled group （P 〈 0.01 ）. Conclusion Uri nary kallidinogenase could selectively expand ischemic vessel, open collateral circulation, and promote the formation of new vessels,if combined with edaravone treating moderate and severe acute cerebral infarction, it could significantly improve the neurological deficit, reduce disability rate and increase the safety.

关 键 词：尤瑞克林 依达拉奉 急性脑梗死 

分 类 号：R743.3[医药卫生—神经病学与精神病学]